10-K: PowerUp Acquisition Corp. Files 10-K, Details Merger Agreement and Financials

PowerUp Acquisition Corp.'s 10-K filing outlines its financials, merger agreement with Visiox Pharmaceuticals, and key operational details.

Summary

• PowerUp Acquisition Corp., a blank check company, filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The company's primary focus is to complete a business combination, with a current emphasis on the pharmaceutical sector.
• As of December 31, 2023, PowerUp had approximately $19.9 million available in its trust account for a business combination.
• The company reported a net income of $4.46 million for 2023, primarily due to interest income from the trust account.
• PowerUp entered into a merger agreement with Visiox Pharmaceuticals on December 26, 2023, aiming to complete the merger by May 23, 2024.
• The merger agreement includes a share exchange and a potential domestication of PowerUp as a Delaware corporation.
• The company has until May 23, 2024, to complete a business combination, or it will be forced to liquidate.
• Shareholders approved an extension to the deadline from May 23, 2023, to May 23, 2024, resulting in significant share redemptions.
• The company's sponsor agreed to purchase shares and warrants from the original sponsor for $1.00, assuming responsibilities and obligations.
• The company has incurred significant costs in the pursuit of its acquisition plans.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's a merger agreement and some positive financial results, the going concern warning and the short timeline to complete the merger raise significant concerns.

Positives

• The company generated a net income of $4.46 million in 2023, primarily from interest income.
• The company has a definitive merger agreement in place with Visiox Pharmaceuticals.
• The underwriters waived their entitlement to deferred underwriting commissions, improving the company's financial position.
• The company has secured a loan of $250,000 to support operations.

Negatives

• The company has a working capital deficit of $322,105 as of December 31, 2023.
• The company has a limited time to complete a business combination by May 23, 2024.
• The company has incurred significant costs in the pursuit of its acquisition plans.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.

Risks

• The company may not be able to complete its initial business combination by May 23, 2024.
• The company may not be able to obtain additional financing to complete the business combination.
• The company's financial performance may be negatively affected by the lack of an established record of revenue and cash flows of the target business.
• The company's independent registered public accounting firm's report contains an explanatory paragraph that expresses substantial doubt about the company's ability to continue as a going concern.
• The company is an early stage company with no revenue or basis to evaluate its ability to select a suitable business target.

Future Outlook

The company is focused on completing its merger with Visiox Pharmaceuticals by May 23, 2024, and is seeking to raise additional capital to support the transaction. The company's future success depends on the performance of the combined entity after the business combination.

Management Comments

• The management team and board consist of experienced deal makers, entrepreneurs, executives and investors.
• The team is led by Suren Ajjarapu, who has over 25 years of specific experience in growing novel companies, raising capital, mergers and acquisitions and building superior management teams.

Industry Context

The company is operating in the special purpose acquisition company (SPAC) sector, which has seen increased scrutiny and volatility. The company's focus on the pharmaceutical industry aligns with a sector that has potential for high growth but also faces regulatory and market risks.

Comparison to Industry Standards

• The company's financial performance is typical for a SPAC in its pre-merger phase, with net income primarily driven by interest earned on the trust account.
• The company's timeline to complete a business combination is consistent with industry standards, but the deadline of May 23, 2024, creates pressure to finalize the merger with Visiox.
• The company's share redemptions are a common occurrence in the SPAC market, reflecting investor uncertainty and the desire to secure a return of capital.
• The company's sponsor purchase agreement is a common mechanism for aligning incentives and ensuring the completion of a business combination.

Management Changes

Related Party Transactions

• The company pays an affiliate of the original sponsor a monthly fee of $10,000 for office space and administrative services.
• The company's sponsor purchased shares and warrants from the original sponsor for $1.00.
• The company entered into a loan and transfer agreement with the sponsor and SSVK Associates, LLC.
• The company entered into a loan and transfer agreement with the sponsor and Apogee Pharma Inc.
• The company entered into a loan and transfer agreement with the sponsor and Jinal Sheth.

Stakeholder Impact

• Shareholders face the risk of liquidation if the business combination is not completed by May 23, 2024.
• Shareholders may experience dilution if additional shares are issued to complete the merger.
• Employees of the target company, Visiox Pharmaceuticals, may be impacted by the merger.
• Creditors of the company may be impacted by the company's ability to complete the merger and repay its debts.

Next Steps

• The company needs to complete the merger with Visiox Pharmaceuticals by May 23, 2024.
• The company needs to secure additional financing to support the merger and future operations.
• The company needs to complete the domestication process and transition to a Delaware corporation.
• The company needs to obtain shareholder approval for the merger.

Key Dates

Keywords

SPAC, Merger, Acquisition, Pharmaceutical, Business Combination, Visiox Pharmaceuticals, Financials, Warrants, Redemption, Trust Account